Independent DSMB reports zero device-related safety issuesSupports potential clinical benefitTrial sample size re-estimated to strengthen ...

Brazil has approved a new law to partially prohibit live animal testing for cosmetics, and will instead prioritize ...

This article explores innovative drug delivery strategies, including DNA barcoding, shape-engineered nanoparticles and ...

In a now-completed clinical trial, the stem cell therapy Neuronata-R was found to benefit ALS patients with slower disease ...

Horsham: Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) has approved a subcutaneous (SC) ...

Objectives C reactive protein (CRP) is frequently normal in psoriatic arthritis (PsA) despite active disease, complicating ...

The FDA has approved a subcutaneous (SC) induction regimen of guselkumab (Tremfya) for adults with moderately to severely ...

Trinity College Dublin scientists showed that electrical stimulation reprograms macrophages to reduce inflammation and boost healing. This breakthrough could lead to broad therapeutic uses.

Levels of systemic inflammatory markers were reduced following 16 weeks of secukinumab treatment in patients with moderate to severe HS.

Developed by Johnson & Johnson, guselkumab is the first approved fully-human, dual-acting IL-23p19 subunit inhibitor that blocks IL-23 and binds to CD64, a receptor on cells that produce IL-23.4,12,13 ...

Johnson & Johnson announced that the U.S. Food and Drug Administration has approved a subcutaneous induction regimen of TREMFYA for the treatment ...

HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) announced that the U.S. Food and Drug Administration has approved a subcutaneous induction regimen of TREMFYA (guselkumab) for the treatment of adults ...